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Pathology tests have a unique place in chronic disease management. They are used to guide disease 
management, assess risk and compliance, enable early detection of adverse events, complications 
and development of secondary diseases. Primary care clinicians rely on guidelines for common 
chronic diseases such as type 2 diabetes, chronic kidney disease (CKD) and hypertension, to inform 
which tests they recommend to their patients and how frequently they should be done. With rates 
of pathology tests rising – at an estimated annual cost of £1.8bn to primary care in the UK1 - and the 
potential for harm from overtesting, it is important to consider the evidence base for these 
recommendations. In this article, we review monitoring strategies in current UK guidelines for 
patients with type 2 diabetes, CKD, and hypertension, highlighting the uncertainties in these 
guidelines and the need for further research. 
 
 
Box 1: What you need to know 
1. Current UK guidelines for monitoring type 2 diabetes, chronic kidney disease and 
hypertension are largely based on expert opinion; robust evidence for optimal 
monitoring strategies and testing intervals is lacking. 
2. Unnecessary testing in primary care can lead to false positives and false negatives, 
increase workload for clinicians, and increase costs for the health service. 
3. Patients and healthcare professionals should be aware of these uncertainties, when 
making shared decisions about chronic disease monitoring. 
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What is the evidence of uncertainty? 
 
Tests recommended by guidelines  
For the chronic diseases reviewed the recommended tests are similar across guidelines. For 
instance, in type 2 diabetes, the monitoring tests recommended across guidelines are glycated 
haemoglobin (HbA1c), plasma glucose profile, and renal function tests such as estimated glomerular 
filtration rate (eGFR) and urine albumin:creatinine ratio (ACR) (Figure 1). Surprisingly, there is no 
clear recommendation in the SIGN 116 diabetes guideline to routinely measure HbA1c.2 In CKD1-3, 
guidelines recommend testing for eGFR and ACR routinely, but not for serum calcium, phosphate, 
parathyroid hormone, and vitamin D (Figure 2). For hypertension, recommended monitoring tests 
are urine ACR, haematuria, electrolytes and creatinine, total and HDL cholesterol, renal profile, 
Hba1c, lipid profile, blood glucose, and eGFR (Figure 3).  
Box 2: Search strategy and guideline selection 
We searched for published UK guidelines for the management of patients with type 2 diabetes, 
CKD1-3*, or hypertension using the following sources: 
• National Institute for Health and Care Excellence (NICE) 
• Scottish Intercollegiate Guidelines Network (SIGN) 
• Royal Colleges of Pathologists (RCPath), Physicians, and General Practitioners 
• Quality Outcomes Framework (QOF) 
The following guidelines are included in this review: 
• SIGN 116 Management of diabetes (2017) 
• NICE CG127 Hypertension, the clinical management of primary hypertension in adults 
(2011) 
• NICE CG182 Chronic Kidney disease (partial update) (2014) 
• NICE NG28 Type 2 diabetes in adults (2015) 
• NICE PH38 Evidence reviews (Type 2 diabetes: prevention in people at high risk) (2017) 
• RCPath: National minimum retesting intervals in pathology (2015) 
We extracted any guidance on the use of laboratory tests for disease monitoring, the 
recommended frequency of testing, as well as the level of evidence on which the guidance was 
based. Tests recommended specifically in relation to medication monitoring are not included. 
The main limitation of this search strategy is that we did not search the primary literature itself. 
As a consequence, we may have missed evidence that is not picked up by the guidelines or was 
published after the guideline was written. 
*CKD4 and 5 are generally monitored in secondary care and are therefore not included in our analysis. 
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Testing recommendations are scattered across most guidelines with no specific sections on 
monitoring. Consequently, clinicians need to read an entire guideline to get an overview of all 
recommended tests. An overview of monitoring recommendations from several guidelines is 
provided by the RCPath national minimal retesting intervals report, but this document refers to 
outdated guidelines and awaits updating.3 We recommend that future guidelines include a summary 
section on monitoring. 
 
Retesting intervals in guidelines are often missing or unclear  
Recommended frequency of testing varies between guidelines or are sometimes not specified at all. 
For example, SIGN recommends annual testing of renal function in patients with diabetes,2 whereas 
NICE suggest that test intervals should be determined by previous renal function results.4 NICE 
recommends that individual needs are taken into account when determining the frequency of 
monitoring, although it is not specified how testing intervals should be adjusted.5 ‘Blood glucose’ 
should be tested routinely in patients with hypertension to screen for diabetes according to NICE, 
but without stating the frequency.6 
 
Robust evidence for optimal monitoring strategies and testing intervals is lacking 
The majority of these recommendations are based on expert opinion, provided by the respective 
guideline development groups. None of the recommendations are solely based on evidence. Where 
evidence is cited it does not address the fundamental question of whether the test in question is 
necessary or beneficial. For instance, in support of ACR monitoring, SIGN diabetes guideline cites a 
meta-analysis of 10 diagnostic cohort studies in diabetic patients.27 However, these studies 
investigate test performance of ACR, but not whether ACR monitoring has an impact on disease 
progression or mortality in diabetes patients. eGFR and ACR monitoring recommendations in the 
NICE CKD guideline are supported by 11 retrospective cohort studies.4 However, the evidence of 
these 11 studies could not be meta-analysed due to substantial variation in the reference groups 
used, and there was a lack of literature addressing optimal frequency of testing. Evidence was cited 
to justify a recommendation not to monitor a blood marker in one instance, namely parathyroid 
hormone monitoring in CKD.14 Four cross-sectional studies showed that parathyroid hormone 
increased in early stages of CKD, but because there was no consensus that patients with modestly 
elevated parathyroid hormone benefit from treatment, the NICE guideline development group 
recommends that parathyroid hormone should not be monitored in patients with stage 1, 2 and 3 
CKD.  
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There is no evidence to support frequency of testing of any test, in any of the guidelines. 
Recommendations regarding frequency of testing are entirely based on expert opinion. 
 
 
Is ongoing research likely to provide relevant evidence? 
ClinicalTrials.gov, a clinical trial registry, was searched for studies addressing optimising chronic 
disease monitoring, using combinations of the following search terms: “type 2 diabetes”, “chronic 
kidney disease”, “hypertension”, “primary care”, “general practice”, “laboratory test”, and 
“monitoring”. No relevant ongoing studies were identified. There is a lack of scientific studies that 
address optimal monitoring of chronic diseases. Current studies focus of the diagnostic or prognostic 
accuracy of certain tests, but there is significant uncertainty about how to determine optimal testing 
frequency or how to evaluate whether monitoring is appropriate. Uncertainties as to which tests 
should be recommended to monitor people with chronic conditions, and how frequently they should 
be tested, can only be clarified if additional evidence can be generated. 
 
Recommendations for future research 
Research should address the following question: what is the optimal monitoring strategy for type 2 
diabetes, CKD, and hypertension patients? This includes both ‘which tests should be used’, as well as 
‘what is the optimal frequency of testing’. There is a gap in the evidence on the benefits of repeated 
testing on patient outcomes, i.e. disease progression, development of secondary diseases, quality of 
life, and mortality. Although an RCT would provide the highest level of evidence, this may not be 
feasible as a long follow-up will be needed to determine the effect on patient outcomes and 
randomising a group to a ‘no monitoring’ condition may be considered unethical. An observational 
study may be conducted instead. The large variation between regions in testing may allow 
comparison of patient outcomes with certain chronic diseases in ‘low’ and ‘high’ monitoring regions, 
although there would be important sources of bias and confounding to consider in such an analysis. 
The populations in ‘low’ and ‘high’ monitoring regions may be inherently different, for example with 
different sociodemographic or age profiles, and it can be challenging to account for all these 
differences. 
Further research is required, and rigorous research methods should be developed to enable 
evidence-based monitoring of chronic diseases. This evidence should feed into guidance. When 
electronic testing panels are introduced in primary care, these should be flexible enough that they 
can be updated regularly as new evidence becomes available. 
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What should we do in the light of the uncertainty? 
We recommend using the current guidelines where clear testing recommendations are given, as 
they are based on the best available evidence; these guideline recommendations should feed into, 
rather than over-ride, discussions with patients that incorporate their values and preferences. In the 
absence of clear evidence, it is all the more important that clinicians consider with their patients 
which tests are likely to influence disease management. GPs should ensure that there is a clear 
clinical rationale for each test that they perform. As chronic disease monitoring is often delegated to 
nursing staff or healthcare assistants, GPs should consider offering training about these uncertainties 
and potential harms of over-testing to the wider primary care team.  
 
Shared decision making 
Patients’ values and preferences about monitoring should always be taken into account. Some 
patients may prefer more frequent testing, others will opt for less. Information about testing, 
including the uncertainties raised here, should be shared with patients to promote shared decision 
making (box 4). We recommend that clinicians explain to patients that testing is not always a good 
thing, and that there may be harms associated with over-testing. 
 
Avoiding unnecessary testing 
There may be a tendency in the light of uncertainty for GPs or other clinicians involved in chronic 
disease monitoring to err on the side of caution and request additional or more frequent tests ‘just 
in case’. Another reason to do more tests than recommended is to ‘make the most of a blood 
drawing’, i.e. adding monitoring tests before they are due when taking blood for another reason. 
Unnecessary testing in a low prevalence setting such as primary care is more likely to lead to false 
positives, which in turn can lead to cascades of follow-up testing.8 11 This can generate anxiety for 
patients, increased workload for doctors, and increased costs for the health service.9 10 False 
negative results, on the other hand, may lead to false reassurances and delayed diagnosis.11  
 
A substantial proportion of pathology testing may be unnecessary, or even inappropriate. In one 
study of cholesterol testing rates in Oxfordshire, 42-79% of cholesterol tests were estimated as 
potentially unnecessary.12 However, there is no consensus on what an ‘inappropriate’ test is and 
estimates of inappropriate test ordering vary substantially (0.2%–100%).13 Most studies examining 
inappropriate testing, compare testing rates to guideline recommendations, rather to robust 
evidence on what constitutes an “appropriate” or “inappropriate” test. 
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Developing ‘test groups’ for pathology test requests 
Laboratory test software often allows users to create ‘test groups’ so that users can order a panel of 
tests for a given chronic disease with one click. Regional test groups may help reduce unwarranted 
variation in testing for monitoring chronic diseases and reduce overall testing rates.14 We are aware 
that practices often develop their own ‘test groups’ or ‘practice profiles’, and these may include 
other tests, such as full blood count, liver function tests, and lipid profiles, in addition to tests 
recommended by current guidelines. In the absence of a clear clinical rationale, any extra monitoring 
tests are essentially functioning as screening tests for occult disease. We recommend such screening 
should be avoided given the absence of clear benefits and significant risks of false positives.  
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Box 3: How patients were involved in the creation of this article 
We held a discussion workshop with members of the CLAHRC West Health Systems Panel, which 
aims to discuss projects of general health relevance, to gather their views on testing for chronic 
conditions. Participants had chronic conditions requiring blood test monitoring, or family 
members with chronic conditions.  
From a patient perspective which tests are done is rather ‘hidden’ and they felt that the 
GP did not always explain what the tests are. They were surprised that guidelines about 
monitoring are largely based on expert opinion (“I thought the NHS was run on evidence”, one 
participant said) and acknowledged that there is an urgent need to fill this knowledge gap. There 
is a general expectation that tests results are always 100% accurate (“they do thousands of 
these, it’ll be accurate”) and that overtesting can not cause any harms (“Testing can’t quite 
actually harm someone can it?”). This feedback informed the information in the “what patients 
need to know” box. 
Box 4: What patients need to know  
In our view, more frequent testing is rarely helpful for patients, and tends to lead to unnecessary 
follow-up testing, which in turn can lead to unnecessary invasive investigations. We believe, as 
supported by our focus group, that patients are generally receptive to having these risks and 
uncertainties explained to them and value this honesty from their clinicians. At the moment it is 
not known what the optimal way of monitoring is to maximize patients’ benefits. We believe 
that in light of the uncertainty decisions around testing should be shared with patients and 
patients’ preferences and views should be taken into account. 
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Box 5: Education into practice 
• When you order blood tests for your patients, is there always a clear rationale for each 
test? We recommend avoiding ‘just-in-case’ or ‘we-have-always-done’ tests unless there 
is a clear rationale for ordering them. 
• How do you explain to patients which tests they are having and why? How do you 
discuss the limitations of blood tests with patients?  
• Do you use local practice protocols for blood tests in patients with chronic diseases? Do 
these contain any extra tests in addition to those recommended by current guidelines?  
• The frequency of testing is not evidence based, however recommendations for annual 
testing seem a reasonable practical choice until better evidence is available. 
• Think about the last time you talked to a patient about blood test results, to what extent 
do you think the patient understood what the test results meant for them?  
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Figure 1: Guidelines and evidence for type 2 diabetes monitoring tests. 
Tests are referred to by the same names as in each relevant guideline. See Box 2 for full names included guidelines. Abbreviations: ACR, albumin creatinine ratio; CKD, 
chronic kidney disease; eGFR, estimated glomerular filtration rate; HbA1c, haemoglobin A1c; NICE, National Institute for Health and Care Excellence; RCPath, Royal College 
of Pathologists; SIGN; Scotland Intercollegiate Guidelines Network. 
Figure 2: Guidelines and evidence for chronic kidney disease 1-3 (CKD) 
Tests are referred to by the same names as in each relevant guideline. See Box 2 for full names included guidelines. Abbreviations: ACR, albumin creatinine ratio; CKD, 
chronic kidney disease; eGFR, estimated glomerular filtration rate; NICE, National Institute for Health and Care Excellence; PTH, Parathyroid hormone; RCPath, Royal 
College of Pathologists; SIGN; Scotland Intercollegiate Guidelines Network. 
 
Figure 3: Guidelines and evidence for hypertension 
Tests are referred to by the same names as in each relevant guideline. See Box 2 for full names included guidelines. Abbreviations: ACR, albumin creatinine ratio; CKD, 
chronic kidney disease; eGFR, estimated glomerular filtration rate; HbA1c, haemoglobin A1c; HDL, high -density-lipoprotein; NICE, National Institute for Health and Care 
Excellence; RCPath, Royal College of Pathologists; SIGN; Scotland Intercollegiate Guidelines Network. 
 
 11 
 
References 
 
1. O'Sullivan JW, Stevens S, Hobbs FDR, et al. Temporal trends in use of tests in UK primary care, 
2000-15: retrospective analysis of 250 million tests. BMJ 2018;363:k4666. doi: 
10.1136/bmj.k4666 [published Online First: 2018/11/30] 
2. Scottish Intercollegiate Guidelines Network (SIGN). 116 Management of diabetes. A national 
clinical guideline 2010 
3. Lang T, Croal B. National minimum retesting intervals in pathology: A final report detailing 
consensus recommendations for minimum retesting intervals for use in pathology. The Royal 
College of Pathologists 2015 
4. National Institute for Health and Care Excellence (NICE). Clinical Guideline 182. Chronic kidney 
disease (partial update). National Clinical Guideline Centre 2014 
5. National Institute for Health and Care Excellence (NICE). Clinical Guideline Update (NG28). Type 2 
diabetes in adults. Internal Clinical Guidelines Team 2015 
6. National Institute for Health and Clinical Excellence (NICE). Clinical Guideline 127. Hypertension. 
National Clinical Guideline Centre 2011 
7. Ewald B, Attia J. Which test to detect microalbuminuria in diabetic patients? A systematic review. 
Aust Fam Physician 2004;33(7):565-7, 71. [published Online First: 2004/08/11] 
8. Deyo RA. Cascade effects of medical technology. Annu Rev Public Health 2002;23:23-44. doi: 
10.1146/annurev.publhealth.23.092101.134534 [published Online First: 2002/03/23] 
9. Hobbs FDR, Bankhead C, Mukhtar T, et al. Clinical workload in UK primary care: a retrospective 
analysis of 100 million consultations in England, 2007-14. Lancet 2016;387(10035):2323-30. 
doi: 10.1016/S0140-6736(16)00620-6 [published Online First: 2016/04/10] 
10. Petrie KJ, Sherriff R. Normal diagnostic test results do not reassure patients. Evid Based Med 
2014;19(1):14. doi: 10.1136/eb-2013-101393 [published Online First: 2013/07/13] 
11. Bennett CM, Guo M, Dharmage SC. HbA(1c) as a screening tool for detection of Type 2 diabetes: 
a systematic review. Diabet Med 2007;24(4):333-43. doi: 10.1111/j.1464-5491.2007.02106.x 
[published Online First: 2007/03/21] 
12. Doll H, Shine B, Kay J, et al. The rise of cholesterol testing: how much is unnecessary. Br J Gen 
Pract 2011;61(583):e81-8. doi: 10.3399/bjgp11X556245 [published Online First: 2011/02/01] 
13. O'Sullivan JW, Albasri A, Nicholson BD, et al. Overtesting and undertesting in primary care: a 
systematic review and meta-analysis. BMJ Open 2018;8(2):e018557. doi: 10.1136/bmjopen-
2017-018557 [published Online First: 2018/02/15] 
14. Whiting D, Croker R, Watson J, et al. Optimising laboratory monitoring of chronic conditions in 
primary care: a quality improvement framework BMJ Open Quality 2019;8(e000349) doi: 
10.1136/bmjoq-2018-000349  
 
